Life Science leaders from across the UK have welcomed a new agreement that will make it easier for life-changing medicines and vaccines research and development to take place across different parts of the UK.
Making sure patients continue to get the medicines they need is of upmost importance as we negotiate the UK’s withdrawal from the EU.
The ABPI is delighted to announce the appointment of Professor Carole Longson MBE as Chief Scientific Officer at the Association of the British Pharmaceutical Industry (ABPI). Carole joins the ABPI from her current role as Executive Director and Board Member at the National Institute for Health and...
As the new AMR Industry Alliance launches its first progress report, ABPI chief executive Mike Thompson welcome the industry’s willingness to work collaboratively to detect, prevent and control AMR.
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
The ABPI have responded today to an announcement by the Department of Health & Social Care who have published a 12 week consultation seeking views from interested parties on the recommendations in the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP).
On Wednesday 21 February, Health and Social Care Secretary Jeremy Hunt announced that Baroness Julia Cumberlege will lead a review into how the NHS responds to safety concerns raised by patients about medicines or medical devices.
The better you understand what’s heading your way, the better you can prepare and plan for the future. Identifying and planning for the availability of new innovative medicines and treatments in the pharmaceutical pipeline is no different.